Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Nurix Therapeutics, Inc. (NRIX) had Income from Continuous Operations of $-193.57M for the most recently reported fiscal year, ending 2024-11-30.
| Income Statement Financials | |
$54.55M |
|
$-193.57M |
|
-- |
|
$54.55M |
|
$267.58M |
|
$-213.03M |
|
$19.73M |
|
$-193.30M |
|
$-193.30M |
|
$-193.57M |
|
|
Income from Continuous Operations |
$-193.57M |
$-193.57M |
|
$-193.57M |
|
$-213.03M |
|
$-207.89M |
|
67.12M |
|
67.12M |
|
$-2.88 |
|
$-2.88 |
|
| Balance Sheet Financials | |
$619.39M |
|
$17.76M |
|
$49.96M |
|
$669.34M |
|
$95.85M |
|
-- |
|
$46.50M |
|
$142.35M |
|
$526.99M |
|
$526.99M |
|
$526.99M |
|
75.87M |
|
| Cash Flow Statement Financials | |
$-172.58M |
|
$-257.71M |
|
$485.67M |
|
$55.53M |
|
$110.90M |
|
$55.37M |
|
$33.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-390.52% |
|
-390.52% |
|
-381.10% |
|
-354.36% |
|
-354.85% |
|
$-181.86M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
-- |
|
-- |
|
-- |
|
-36.73% |
|
-36.73% |
|
-28.92% |
|
-36.73% |
|
$6.95 |
|
$-2.71 |
|
$-2.57 |
|